People who have been treated with the type 2 diabetes medication Actos (pioglitazone) for more than six months may be at greater risk of developing bladder cancer, even if they were on a low dose, according to a new study published in the Journal of Korean Medical Science and reported by Cancer Monthly. In 2011, studies showed long-term use (12 months or greater) of Actos increased the risk for bladder cancer. As a result, some countries banned the drug. The U.S. Food and Drug Administration (FDA) ordered that Actos and its generic equivalents include a warning on their safety labels ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.